Cipla, a global pharmaceutical leader, has partnered with ImmunoACT to introduce talicabtagene autoleucel in Africa. This is ...

Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

Amid growing evidence suggesting circadian rhythms play a critical in the safety and efficacy of CAR T-cell therapy, ...

Cervical cancer treatment evolves with molecular screening and immunotherapies, emphasizing early detection as key to ...

Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an unconventional approach to metastatic cancer: instead of going after cancer cells ...

Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an unconventional approach to metastatic cancer: instead of going after cancer cells ...

The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...

Universal gene‑edited CAR‑T therapies turn donor T cells into off‑the‑shelf cancer treatments, cutting delays and costs while ...

A small number of cancer cells with the ability to change their identities and behaviors appear to be a key driver of cancer ...

Michael Kalos, Ph.D., is the founder and managing director of Next Pillar Consulting, where he advises biopharmaceutical and venture organizations. He is also a Venture Partner with Alloy Therapeutics ...

Under healthy conditions, the intestinal epithelium fully renews itself every three to five days. Aging and exposure to ...